Yang Kwan Mo, Park In Ja, Lee Jong Lyul, Yoon Yong Sik, Kim Chan Wook, Lim Seok-Byung, Kim Na Young, Hong Shinae, Yu Chang Sik, Kim Jin Cheon
Department of General Surgery, University of Ulsan College of Medicine, Gangneung Asan Hospital, Gangneung, Korea.
Division of Colon and Rectal Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Ann Coloproctol. 2019 Feb;35(1):15-23. doi: 10.3393/ac.2018.07.25. Epub 2019 Feb 28.
We evaluate the prognostic value of primary tumor location for oncologic outcomes in patients with colon cancer (CC).
CC patients treated with curative surgery between 2009 and 2012 were classified into 2 groups: right-sided colon cancer (RCC) and left-sided colon cancer (LCC). Recurrence-free survival (RFS) and overall survival (OS) were examined based on tumor stage. Propensity scores were created using eight variables (age, sex, T stage, N stage, histologic grade, presence of lymphovascular invasion/perineural invasion, and microsatellite instability status).
Overall, 2,329 patients were identified. The 5-year RFSs for RCC and LCC patients were 89.7% and 88.4% (P = 0.328), respectively, and their 5-year OSs were 90.9% and 93.4% (P = 0.062). Multivariate survival analyses were carried out by using the Cox regression proportional hazard model. In the unadjusted analysis, a marginal increase in overall mortality was seen in RCC patients (hazard ratio [HR], 1.297; 95% confidence interval [CI], 0.987-1.704, P = 0.062); however, after multivariable adjustment, similar OSs were observed in those patients (HR, 1.219; 95% CI, 0.91-1.633; P = 0.183). After propensity-score matching with a total of 1,560 patients, no significant difference was identified (P = 0.183). A slightly worse OS was seen for stage III RCC patients (HR, 1.561; 95% CI, 0.967-2.522; P = 0.068) than for stage III LCC patients. The 5-year OSs for patients with stage III RCC and stage III LCC were 85.5% and 90.5%, respectively (P = 0.133).
Although the results are inconclusive, tumor location tended to be associated with OS in CC patients with lymph node metastasis, but it was not related to oncologic outcome.
我们评估原发性肿瘤位置对结肠癌(CC)患者肿瘤学结局的预后价值。
将2009年至2012年接受根治性手术治疗的CC患者分为两组:右半结肠癌(RCC)和左半结肠癌(LCC)。根据肿瘤分期检查无复发生存期(RFS)和总生存期(OS)。使用八个变量(年龄、性别、T分期、N分期、组织学分级、是否存在淋巴管侵犯/神经周侵犯以及微卫星不稳定性状态)创建倾向评分。
总共确定了2329例患者。RCC和LCC患者的5年RFS分别为89.7%和88.4%(P = 0.328),其5年OS分别为90.9%和93.4%(P = 0.062)。使用Cox回归比例风险模型进行多变量生存分析。在未调整分析中,RCC患者的总体死亡率略有增加(风险比[HR],1.297;95%置信区间[CI],0.987 - 1.704,P = 0.062);然而,在多变量调整后,这些患者的OS相似(HR,1.219;95% CI,0.91 - 1.633;P = 0.183)。在对总共1560例患者进行倾向评分匹配后,未发现显著差异(P = 0.183)。III期RCC患者的OS略差于III期LCC患者(HR,1.561;95% CI,0.967 - 2.522;P = 0.068)。III期RCC和III期LCC患者的5年OS分别为85.5%和90.5%(P = 0.133)。
尽管结果尚无定论,但在有淋巴结转移的CC患者中,肿瘤位置倾向于与OS相关,但与肿瘤学结局无关。